AVEO Oncology Announces Participation at Two Upcoming Virtual Investor Conferences

Rhea-AI Summary

AVEO Oncology (NASDAQ: AVEO) recently announced its participation in two virtual investor conferences. The Stifel 2021 Healthcare Conference is scheduled for November 15 at 1:20 p.m. ET, while the 4th Annual Evercore ISI Healthconx Conference will take place on November 30 at 12:35 p.m. ET. Interested investors can access live webcasts and archived recordings on AVEO's website for up to 30 days post-event. AVEO is dedicated to developing treatments for cancer, including its marketed product FOTIVDA® for renal cell carcinoma.

BOSTON--(BUSINESS WIRE)-- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company, today announced that members of its senior management team will participate in two upcoming virtual investor conferences:

Stifel 2021 Healthcare Conference
Date: Monday, November 15
Time: 1:20 p.m. Eastern Time

4^th Annual Evercore ISI Healthconx Conference
Date: Tuesday, November 30
Time: 12:35 p.m. Eastern Time

A webcast of the fireside chats, or the subsequent archived recordings can be accessed by visiting the Calendar of Events sub-section within the Investors section of the Company’s website at www.aveooncology.com. A replay of the webcast will be archived for 30 days following the presentation date.

About AVEO Pharmaceuticals, Inc.

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications, and has other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of AVEO within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Actual results or events could differ materially due to a number of important factors, including risks discussed in the sections titled “Risk Factor Summary,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Liquidity and Capital Resources” included in AVEO’s most recent Annual Report on Form 10-K, its quarterly reports on Form 10-Q and in other filings that AVEO makes with the SEC. The forward-looking statements in this press release represent AVEO’s views as of the date of this press release. AVEO anticipates that subsequent events and developments may cause its views to change. While AVEO may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing AVEO’s views as of any date other than the date of this press release

View source version on businesswire.com: https://www.businesswire.com/news/home/20211110005266/en/

AVEO Public Relations Contact:

David Pitts, Argot Partners

(212) 600-1902

aveo@argotpartners.com

AVEO Investor Relations Contact:

Hans Vitzthum, LifeSci Advisors

(617) 430-7578

hans@lifesciadvisors.com

Source: AVEO Oncology

FAQ

When is AVEO participating in the Stifel 2021 Healthcare Conference?

AVEO will participate in the Stifel 2021 Healthcare Conference on November 15 at 1:20 p.m. Eastern Time.

What date is the 4th Annual Evercore ISI Healthconx Conference for AVEO?

The 4th Annual Evercore ISI Healthconx Conference will be on November 30 at 12:35 p.m. Eastern Time.

How can I access AVEO's conference webcasts?

You can access the live webcasts and archived recordings on AVEO's website under the Calendar of Events in the Investors section.

What is AVEO's main product?

AVEO markets FOTIVDA® (tivozanib) for the treatment of relapsed or refractory renal cell carcinoma (RCC).

What is the focus of AVEO Oncology?

AVEO is focused on developing biopharmaceuticals for cancer treatment, particularly through its product FOTIVDA and other investigational programs.